Therapies that address the root cause of age

Sironax is a clinical-stage biotechnology company focused on developing innovative therapies for age-related degenerative diseases. Established in 2017, the company has developed a diverse pipeline that targets critical biological mechanisms associated with these diseases, such as regulated cell death, neuroprotective pathways, and neuroinflammation. Sironax is actively conducting early clinical studies for its lead candidates, SIR2446 and SIR9900, while also engaging in ongoing preclinical research to further advance its therapeutic offerings.

The company's research emphasizes a deep understanding of the underlying mechanisms of age-related conditions, which informs its approach to drug development. By focusing on regulated cell death and neuroprotective strategies, Sironax aims to create effective treatments that can significantly improve patient outcomes. The company has made notable progress in its clinical trials, including the completion of Phase 1 studies, which positions it well for future advancements in the biotechnology landscape.

China

Sironax is a clinical-stage biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related degenerative diseases. Since its founding in 2017, Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways and neuroinflammation. Sironax is currently conducting early clinical studies with SIR0365 and SIR2446, in addition to ongoing preclinical research.

Sironax

Company Details